MCL Literature Feed

This 20-year Taiwanese retrospective study confirms that frontline rituximab, intensive chemotherapy, and autologous transplant are associated with improved survival, validating these established strategies in a real-world Asian cohort.

Epigenetic profiling reveals a unique DNA methylation signature for B-cell prolymphocytic leukemia, providing a novel biomarker to differentiate it from its mimics, including mantle cell lymphoma.

This large retrospective study of 476 MCL patients aged ≥80 provides crucial real-world outcome data, informing treatment selection and expectations in the very elderly population.

In newly diagnosed MCL, PET/CT-based bone marrow assessment has greater prognostic value than biopsy and is incorporated into a new MCL-PET-I index for improved risk stratification.

This retrospective case series strengthens the link between ibrutinib and delayed-onset uveitis, a potentially vision-threatening toxicity that resolves upon drug cessation, highlighting a key clinical management consideration.

Analysis of European MCL Network trial data shows specific gene mutations predict patient outcomes, providing a genetic basis for risk stratification to guide therapy selection beyond clinical scores.

Quantitative measurement of Cyclin D1 protein reveals that higher levels are paradoxically associated with better overall survival, establishing a novel, independent prognostic biomarker for MCL risk stratification.

Long-term follow-up after autologous stem cell transplant in MCL is critical for detecting late relapses and managing treatment-related toxicities, guiding post-transplant surveillance strategies.

Malignant effusions, frequently caused by blastoid MCL, are characterized by a T/B cell ratio <1, providing a crucial diagnostic marker from cytological samples.

This large, single-center retrospective study characterizes the aggressive nature and poor outcomes of MCL with cutaneous involvement, providing crucial real-world data for managing this rare presentation.

Bendamustine-induced lymphopenia in frontline MCL resolves by 12 months, suggesting a minimum 9-month wait before leukapheresis for CAR-T therapy to ensure sufficient lymphocyte collection.

In a small retrospective study of nine untreated aggressive MCL patients, adding a BTKi to chemoimmunotherapy achieved a 100% objective response rate with manageable toxicity, suggesting a promising frontline strategy.

A new LSM gene expression index identifies MCL patients with poor survival by impacting cell division and RNA splicing, proposing LSM proteins as novel prognostic biomarkers and therapeutic targets.

This retrospective study confirms poor outcomes for blastoid MCL with chemo-immunotherapy, advocating for upfront 2nd/3rd generation BTKi-based therapies to improve survival in this high-risk population.

p53 immunohistochemistry is a practical biomarker for identifying high-risk MCL patients, helping to stratify prognosis and guide selection of more intensive or novel therapies.

Real-world US Medicare data shows elderly MCL patients post-cBTKi have a dismal median OS of 9.4 months and high costs, highlighting the urgent need for effective therapies.

Bioinformatic analysis of public datasets identified key genes and pathways driving bortezomib resistance in MCL, providing potential biomarkers and therapeutic targets for the relapsed/refractory setting.

SOX11-negative, CCND1-rearranged large B-cell lymphomas can arise via a DLBCL-like mechanism (aberrant CSR/SHM), distinguishing them genetically from classic MCL and highlighting a potential diagnostic challenge.

In younger, BTKi-naïve MCL patients with late relapse (>24 months), second-line BTKi significantly improved PFS and OS versus chemoimmunotherapy, establishing it as the preferred approach in this setting.

Spatial multiomics reveals CD163+ macrophages activate the MAPK prosurvival pathway in MCL cells, identifying MAPK inhibitors as a potential therapy for patients with high macrophage infiltration.

This large, real-world French database study on ibrutinib focuses exclusively on patients with CLL, providing no specific data or insights relevant to mantle cell lymphoma.

A high monocyte-to-platelet ratio (MPR ≥ 3) at diagnosis is a novel, independent prognostic biomarker for inferior progression-free survival in transplant-ineligible mantle cell lymphoma patients.

This large, real-world study confirms cytarabine-based induction provides the longest front-line PFS (68 months), while second-line chemotherapy outcomes are poor (14 months PFS), highlighting the need for novel agents.

This study identifies a rare CD5/SOX11 double-negative pleomorphic MCL, showing CCND1 rearrangement is the key feature to differentiate it from cyclin D1-positive DLBCL, ensuring correct diagnosis.

This study analyzes molecular responses in exceptional responders to the BTKi tirabrutinib, aiming to identify biomarkers for deep, durable remissions in relapsed/refractory mantle cell lymphoma.

This multicenter retrospective study analyzes real-world maintenance strategies in mantle cell lymphoma, providing evidence to guide treatment selection and duration after initial therapy.

This paper identifies a subset of MCL with IRTA1-positive reactive marginal zone expansion, highlighting a potential diagnostic pitfall for pathologists distinguishing it from marginal zone lymphoma.

This paper likely provides a retrospective or real-world analysis of the incidence, types, and risk factors for infections in MCL, informing clinical decisions on prophylaxis and supportive care.

This large Chinese retrospective study of blastoid/pleomorphic MCL links progression of disease within 12 months (POD12) to a distinct mutation profile (TP53, SMARCA4) and poor prognosis.

Bendamustine is a feasible alternative lymphodepletion for brexu-cel in MCL, showing comparable efficacy to standard cy/flu with less cytopenia, providing a critical option during drug shortages.